Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BGXXNASDAQ:CLRBNASDAQ:GLYCNASDAQ:VRAX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBGXXBright Green$0.05$0.03▼$0.54$11.47M-0.26360,154 shs25,935 shsCLRBCellectar Biosciences$0.26+7.4%$0.28$0.22▼$3.42$12.17M0.481.15 million shs1.13 million shsGLYCGlycoMimetics$0.21-2.3%$0.23$0.14▼$0.63$13.76M1.76.44 million shs370,917 shsVRAXVirax Biolabs Group$0.96-1.6%$1.04$0.82▼$9.00$3.10M1.842.08 million shs33,832 shs7 Stocks to Buy And Hold ForeverEnter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBGXXBright Green0.00%0.00%0.00%+50.00%-70.54%CLRBCellectar Biosciences-2.81%-1.29%-17.07%-14.50%-91.70%GLYCGlycoMimetics-4.63%-12.09%-16.24%-16.37%-18.28%VRAXVirax Biolabs Group-7.24%-6.35%-12.25%-43.04%+9.44%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBGXXBright GreenN/AN/AN/AN/AN/AN/AN/AN/ACLRBCellectar Biosciences1.2474 of 5 stars3.22.00.00.01.10.00.6GLYCGlycoMimetics2.0152 of 5 stars0.04.00.04.63.31.70.0VRAXVirax Biolabs Group3.0135 of 5 stars3.55.00.00.02.21.70.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBGXXBright Green 0.00N/AN/AN/ACLRBCellectar Biosciences 2.33Hold$12.504,652.85% UpsideGLYCGlycoMimetics 2.33HoldN/AN/AVRAXVirax Biolabs Group 3.00Buy$3.00209.28% UpsideCurrent Analyst Ratings BreakdownLatest VRAX, BGXX, CLRB, and GLYC Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/14/2025CLRBCellectar BiosciencesMaxim GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Hold3/31/2025VRAXVirax Biolabs GroupHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$3.003/21/2025GLYCGlycoMimeticsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight(Data available from 5/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBGXXBright GreenN/AN/AN/AN/A$0.06 per shareN/ACLRBCellectar BiosciencesN/AN/AN/AN/A($0.96) per shareN/AGLYCGlycoMimetics$10K1,348.72N/AN/A$0.08 per share2.61VRAXVirax Biolabs Group$84.87K36.95N/AN/A$2.00 per share0.49Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBGXXBright Green-$13.13M-$0.06N/AN/AN/AN/A-88.37%-55.30%N/ACLRBCellectar Biosciences-$42.77M-$0.73N/AN/AN/AN/AN/A-191.22%8/11/2025 (Estimated)GLYCGlycoMimetics-$37.88M-$0.46N/AN/AN/AN/A-230.74%-177.39%8/14/2025 (Estimated)VRAXVirax Biolabs Group-$6.73MN/A0.00∞N/AN/AN/AN/AN/ALatest VRAX, BGXX, CLRB, and GLYC EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2025Q1 2025GLYCGlycoMimetics-$0.05-$0.04+$0.01-$0.04N/AN/A5/13/2025Q1 2025CLRBCellectar Biosciences-$0.17-$0.13+$0.04-$0.14N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBGXXBright GreenN/AN/AN/AN/AN/ACLRBCellectar BiosciencesN/AN/AN/AN/AN/AGLYCGlycoMimeticsN/AN/AN/AN/AN/AVRAXVirax Biolabs GroupN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBGXXBright GreenN/A0.010.01CLRBCellectar BiosciencesN/A1.771.77GLYCGlycoMimeticsN/A1.921.92VRAXVirax Biolabs GroupN/A11.5711.39Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBGXXBright Green7.83%CLRBCellectar Biosciences16.41%GLYCGlycoMimetics75.19%VRAXVirax Biolabs Group8.61%Insider OwnershipCompanyInsider OwnershipBGXXBright Green62.55%CLRBCellectar Biosciences3.70%GLYCGlycoMimetics8.70%VRAXVirax Biolabs Group45.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBGXXBright Green2191.17 million71.59 millionNo DataCLRBCellectar Biosciences1046.08 million44.38 millionOptionableGLYCGlycoMimetics5064.53 million58.90 millionOptionableVRAXVirax Biolabs Group53.23 million1.78 millionNot OptionableVRAX, BGXX, CLRB, and GLYC HeadlinesRecent News About These CompaniesVirax Biolabs Group (NASDAQ:VRAX) Stock Price Up 2% - Here's What HappenedMay 24, 2025 | americanbankingnews.comHC Wainwright & Co. Initiates Coverage of Virax Biolabs Group (VRAX) with Buy RecommendationMarch 31, 2025 | msn.comVirax Biolabs' Investigational Diagnostic Tests Has An Attractive Market Opportunity', Analyst Initiates With Buy RatingMarch 31, 2025 | benzinga.comVirax Biolabs Launches Clinical Study on T Cell DysfunctionMarch 18, 2025 | msn.comVirax Biolabs Enrolls First Patients in Clinical Study Assessing T cell Dysfunction in Post-acute Infection SyndromesMarch 18, 2025 | prnewswire.comVirax Biolabs Presents Data on T-Cell Dysfunction in Post-acute Infection Syndromes at the 19th World Immune Regulation MeetingMarch 13, 2025 | prnewswire.comVirax Biolabs to Present at 19th World Immune Regulation MeetingMarch 5, 2025 | prnewswire.comVirax Biolabs Aligns with US Health Department on Vaccine TransparencyFebruary 25, 2025 | tipranks.comVirax Biolabs Believes Technology Aligns with United States Department of Health and Human Services' Transparency Priority on Vaccine EfficacyFebruary 25, 2025 | prnewswire.comCosmos Health expands distribution of Avian Influenza kitsJanuary 23, 2025 | msn.comCosmos Health Signs Expanded Exclusive Distribution Agreement with Virax Biolabs for Avian Influenza Virus PCR Kits in Saudi Arabia, the UAE, Qatar, and KuwaitJanuary 23, 2025 | accessnewswire.comCosmos Health Secures Exclusive Distribution Agreement with Virax Biolabs for Avian Influenza Virus PCR Kits in Greece and Cyprus, with Additional Rights in Select European and GCC CountriesJanuary 13, 2025 | accesswire.comVirax Biolabs Group Ltd (VRAX) Stock: Beyond the Surface of Its Performance?December 19, 2024 | bovnews.comVirax Biolabs Announces Strategic Goals and Developments for 2025December 18, 2024 | markets.businessinsider.comVirax Biolabs' CEO James Foster Issues Letter to ShareholdersDecember 17, 2024 | prnewswire.comVirax Biolabs Announces Agreement with Tebubio to Expand Distribution of ImmuneSelect Across the European Union, Norway, and SwitzerlandDecember 10, 2024 | prnewswire.comVirax Biolabs Sees Asset Growth Amid Financial LossNovember 22, 2024 | markets.businessinsider.comVirax Biolabs announces distribution agreement with Europa BiositeOctober 24, 2024 | markets.businessinsider.comVirax Biolabs Expands Reach with Europa Biosite DealOctober 24, 2024 | markets.businessinsider.comVirax Biolabs Signs Distribution Agreement With Europa Biosite To Sell ImmuneSelect; Stock UpOctober 23, 2024 | markets.businessinsider.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeVRAX, BGXX, CLRB, and GLYC Company DescriptionsBright Green NASDAQ:BGXXBright Green Corporation focuses on the cultivation, manufacture, and sale of cannabis and cannabis-related products. Its products are used in research, pharmaceutical applications, and affiliated exports. The company was incorporated in 2019 and is based in Grants, New Mexico.Cellectar Biosciences NASDAQ:CLRB$0.26 +0.02 (+7.40%) Closing price 04:00 PM EasternExtended Trading$0.26 0.00 (-0.76%) As of 04:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study for patients with B-cell malignancies; Phase 2a clinical study for patients with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia cohort, r/r multiple myeloma (MM) cohort, and r/r non-Hodgkin's lymphoma cohort; Phase 1 clinical study for r/r pediatric patients with select solid tumors, lymphomas, and malignant brain tumors; and Phase 1 clinical study for r/r head and neck cancer. The company also develops CLR 1900, a PDC chemotherapeutic program that is in the preclinical development stage to treat solid tumors. It has collaborative with Orano Med to develop CLR 12120 Series; and LegoChemBio. The company was founded in 2002 and is headquartered in Florham Park, New Jersey.GlycoMimetics NASDAQ:GLYC$0.21 -0.01 (-3.30%) As of 04:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.GlycoMimetics, Inc., a biotechnology company, focuses on the discovery and development of therapies for cancers and inflammatory diseases in the United States. It develops uproleselan, an E-selectin antagonist, which is used in combination with chemotherapy to treat acute myeloid leukemia (AML), as well as completed phase 3 trial to treat relapsed/refractory AML. The company also develops various other programs, including GMI-1687, an antagonist of E-selectin to treat vaso-occlusive crisis; and GMI-2093, a galectin-3 carbohydrate-binding protein. In addition, its portfolio comprises GMI-1359, which targets e-selectin and a chemokine receptor for the treatment of osteosarcoma. The company has a cooperative research and development agreement with the National Cancer Institute; and a collaboration and license agreement with Apollomics (Hong Kong) Limited for the development and commercialization of uproleselan and GMI-1687. GlycoMimetics, Inc. was incorporated in 2003 and is headquartered in Rockville, Maryland.Virax Biolabs Group NASDAQ:VRAX$0.96 -0.02 (-1.64%) Closing price 03:59 PM EasternExtended Trading$0.94 -0.01 (-1.36%) As of 04:09 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Virax Biolabs Group Limited, a biotechnology company, sells, distributes, and markets diagnostics test kits for the prevention, detection, diagnosis, and risk management of viral diseases in the field of immunology. The company provides rapid antibody IgC/IgM tests, antigen tests, polymerase chain reaction rapid tests, and neutralizing antibody tests under the ViraxClear brand name. It also develops T-Cell IVD test kit for COVID-19, which intend to adapt for immunological profiling against multiple viral threats under the ViraxImmune Brand, as well as a proprietary mobile application for ViraxImmune that presents an individual's immunological profiling data and provide advice on the users' immune system. It serves clinics, pharmacies, laboratories, hospitals, and other groups, as well as corporations, pharmaceutical companies, research institutions, hospital systems, and public and private institutions. The company operates in Europe, South America, the Asia Pacific, Sub-Saharan Africa, and internationally. The company was formerly known as Virax Biolabs (Cayman) Limited and changed its name to Virax Biolabs Group Limited in September 2021. Virax Biolabs Group Limited was incorporated in 2021 and is headquartered in London, the United Kingdom. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Hormel Stock Near Lows, But Tariff Relief Could Boost Outlook Salesforce’s Stock Price Presents an Opportunity to Buy NVIDIA Will Set a New High Soon, Then Keep Rallying, Here’s Why Goodyear Stock Surges 28% in 2025: Is More Growth Ahead? Intel's Loss Is Broadcom's Gain as AVGO Dominates Networking Target's Big Bet: Is It a Cheap Stock or a Value Trap? Dividend Investors Looking for an Edge? 3 Stocks Insiders Bought Toyota Supercharges Joby: $250M Capital Infusion Ignites Stock Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
